Verax Biomedical

Verax Biomedical is a venture-backed diagnostics company addressing the significant risk of bacterial contamination in platelet transfusions. Its core technology, the Pan Genera Detection (PGD) platform, enables rapid, near-patient testing that has received FDA clearance to extend platelet shelf life to seven days, improving safety, availability, and cost-efficiency for blood centers and hospitals. The company is led by a seasoned management team and supported by a distinguished Medical Advisory Committee, positioning it as a key player in responding to evolving FDA guidance on bacterial risk mitigation in the blood supply.

Patented Pan Genera Detection (PGD) technology: a rapid, lateral-flow immunoassay that detects conserved bacterial antigens common to a broad range of gram-positive and gram-negative bacteria, enabling near-transfusion testing.

Verax competes in the platelet bacterial detection market primarily against pathogen reduction technology (PRT) systems (e.g., Cerus's INTERCEPT, Terumo BCT's Mirasol) which inactivate pathogens but are more costly and complex. Other competitors include alternative rapid tests and traditional but slower bacterial culture methods. Verax's key differentiators are the simplicity, speed, and cost-effectiveness of its test, coupled with the FDA-cleared benefit of 7-day platelet storage.